In the world of clinical trials, research sites occasionally have a strange feeling of déjà vu—”It’s you again?” That familiar face showing up for another screening visit may not just be coincidence. In fact, it’s often a warning sign of a growing issue in clinical research: professional patients and duplicate subjects in clinical research. These …
Studies in clinical research show that duplicate or professional trial participants—individuals enrolling in multiple studies simultaneously—are far more common than many sponsors realize. Rates as high as 10% have been reported in therapeutic areas beyond psychiatry, including dermatology, ophthalmology, respiratory, and others. Each duplicate research subject can skew efficacy, safety, and overall trial integrity. The data: …
Clinical trials are complex, high-stakes endeavors where every detail matters — yet one hidden risk continues to undermine studies across all therapeutic areas: duplicate and professional research subjects. You may believe your internal checks, EDC reviews, or sponsor-specific solutions have you covered. The reality?Most systems only detect duplicate subjects after they’ve already dosed — or …
When a clinical trial misses its primary endpoint, the root cause is rarely just the science — more often, it’s hidden threats to the data itself. One of the most overlooked risks is the presence of duplicate research subjects or professional research subjects who enroll in multiple studies or across multiple sites, undermining results and …
Verified Clinical Trials (VCT), the world’s largest research subject database registry, has expanded operations in Japan through a collaboration with Medical Revolutions Japan (MRJ) and the Japan Association of Contract Institutes for Clinical Pharmacology (JACIC). This partnership helps address the growing global challenge of duplicate subjects in clinical trials and professional patients, which can undermine …
Verified Clinical Trials (VCT) is proud to announce our participation at the upcoming American Diabetes Association (ADA) annual meeting. As clinical research in diabetes, obesity, and GLP-1 therapies continues to expand at a record pace, VCT remains committed to delivering innovative solutions that safeguard data integrity, improve participant safety, and optimize trial outcomes by preventing …
The race to develop and commercialize GLP-1-based therapies for obesity and diabetes has created unprecedented momentum in clinical research. Dozens of sponsors and CROs are simultaneously conducting trials—often in overlapping geographic regions—with many vying for access to the same pool of patients. While this represents exciting progress in metabolic disease treatment, it also presents a …
https://healthtechcurated.com/regulatory-and-compliance/how-does-vct-protect-clinical-trials-from-duplicate-subjects/ In the complex realm of clinical trials, preventing the enrollment of duplicate and professional research subjects is critical for maintaining data integrity and ensuring participant safety. As trials expand with overlapping indications and global participation, the risk of unethical subject enrollment increases. These duplicate reseaerch subjects, who join multiple studies without observing necessary washout …
Detecting and preventing protocol violations before they ever happen. In today’s complex clinical trial landscape, one issue continues to fly under the radar—duplicate research subjects and professional research subjects. These individuals enroll in multiple trials simultaneously or too close together, often crossing therapeutic areas, sponsors, and trial phases. Left unchecked, these subjects introduce significant risk …
The Verified Clinical Trials (VCT) team is excited to attend the 2025 ASCP Annual Meeting, currently taking place in Tucson, Arizona. As the premier event hosted by the American Society of Clinical Psychopharmacology, ASCP brings together global leaders advancing psychiatry and CNS (central nervous system) drug development—and VCT is proud to support that mission. Verified …
